A manufacturer of healthcare products including personal protective equipment has accused a newly incorporated company of trying to confuse consumers during the Covid-19 pandemic.
A US federal appeals court has upheld a 42-month prison sentence for an ex-employee of DuPont Industrial Biosciences who stole trade secrets from the firm.
Biotechnology company Ravgen has accused Myriad Genetics and Myriad Women’s Health of infringing two patents covering non-invasive DNA testing technology.
Biogen has lost its long-standing fight to recover billions of dollars in royalties from the sale of a multiple sclerosis (MS) drug, after the US Court of Appeals for the Federal Circuit rejected Biogen’s request that it reconsider its own ruling.
A $2.3 trillion spending bill passed by the US Congress yesterday, December 21 includes a proposed change to the laws concerning biologic drugs.
The US Court of Appeals for the Federal Circuit yesterday, December 21, upheld Eli Lilly’s success in barring the sale of a copycat version of cancer treatment Alimta (pemetrexed disodium).
The US International Trade Commission has sided in favour of AbbVie/Allergan, which argued that a rival should be prevented from importing a low-cost version of its Botox treatment into the US for 21 months, because it had stolen trade secrets.
The UK is facing a divergence in supplementary protection certificate regulations across the Irish Sea post-Brexit.
Eli Lilly is expanding its genetics business with the $880 million purchase of Prevail Therapeutics, in a deal that could rise to more than $1 billion.
Medical device company Nevro has agreed to drop a patent infringement suit which accused Boston Scientific of infringing patents related to spinal cord stimulation (SCS) therapy.